Baur A, Stäbler A, Bartl R, Lamerz R, Scheidler J, Reiser M
Department of Diagnostic Radiology, University of Munich (Grosshadern), Germany.
Skeletal Radiol. 1997 Jul;26(7):414-8. doi: 10.1007/s002560050257.
To quantify gadolinium-related enhancement in the bone marrow of the spine in normals and in patients with homogeneous diffuse malignant bone marrow infiltration.
The patients consisted of two groups: group 1 comprised 94 healthy adults (18-86 years) without bone marrow disease and group 2 comprised 30 patients with homogeneous diffuse malignant bone marrow infiltration due to myeloma (n = 20) or breast carcinoma (n = 10). All patients received intravenous gadopentetate dimeglumine (Gd-DTPA), 0.1 mmol/kg body weight. Pre- and postcontrast signal intensity (SI) on T1-weighted spin-echo (SE) images (TR/TE: 572 ms/15 ms) was measured over a region of interest (ROI) and the percentage SI increase was calculated. The results were confirmed by bone marrow biopsy (n = 20) and clinical parameters (n = 10). Dynamic contrast-enhanced studies using a spoiled gradient-recalled-echo (GRE) sequence (TR/TE/alpha: 68 ms/6 ms 75 degrees) were performed in 10 controls with normal bone marrow.
Contrast material enhancement in healthy persons can vary greatly (range 3-59%, mean 21%, SD 11%). With increasing age there is a significant decrease in contrast enhancement (Pearson's correlation, P < 0.01). The percentage SI increase in patients with intermediate-grade (biopsy 20-50 vol%) and high-grade (biopsy > 50 vol%) diffuse malignant bone marrow infiltration was significantly higher than in normals (mean 67%, SD 34%, P < 0.001). Low-grade (biopsy < 20 vol%) diffuse malignant bone marrow infiltration can not be assessed by non-enhanced T1-weighted SE images or Gd-DTPA application. In conclusion, contrast material enhancement in healthy persons can vary greatly and is dependent on age, while intermediate-grade and high-grade diffuse malignant bone marrow infiltration can be objectively assessed with SI measurements.
量化正常人和弥漫性恶性骨髓浸润患者脊柱骨髓中钆相关的强化情况。
患者分为两组:第1组包括94名无骨髓疾病的健康成年人(18 - 86岁),第2组包括30名因骨髓瘤(n = 20)或乳腺癌(n = 10)导致弥漫性恶性骨髓浸润的患者。所有患者均静脉注射钆喷酸葡胺(Gd - DTPA),剂量为0.1 mmol/kg体重。在T1加权自旋回波(SE)图像(TR/TE:572 ms/15 ms)上测量感兴趣区(ROI)的对比剂注射前后信号强度(SI),并计算SI增加百分比。结果通过骨髓活检(n = 20)和临床参数(n = 10)进行验证。对10名骨髓正常的对照者进行了使用扰相梯度回波(GRE)序列(TR/TE/α:68 ms/6 ms 75°)的动态对比增强研究。
健康人对比剂强化差异很大(范围3% - 59%,平均21%,标准差11%)。随着年龄增长,对比增强显著降低(Pearson相关性,P < 0.01)。中度(活检20% - 50%体积)和高度(活检> 50%体积)弥漫性恶性骨髓浸润患者的SI增加百分比显著高于正常人(平均67%,标准差34%,P < 0.001)。低度(活检< 20%体积)弥漫性恶性骨髓浸润无法通过非增强T1加权SE图像或应用Gd - DTPA进行评估。总之,健康人对比剂强化差异很大且依赖于年龄,而中度和高度弥漫性恶性骨髓浸润可通过SI测量进行客观评估。